The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections
Abstract
Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics (penicillinase-resistant penicillins [4-12 g iv per day] or vancomycin [1 g iv every 12 h]) in 2 randomized, international trials involving 1092 patients with complicated skin and skin-structure infections. Among 902 clinically evaluable patients, clinical success rates were 83.4% and 84.2% for the daptomycin- and comparator-treated groups, respectively (95% confidence interval, -4.0 to 5.6). Among patients successfully treated with iv daptomycin, 63% required only 4-7 days of therapy, compared with 33% of comparator-treated patients (P<.0001). The frequency and distribution of adverse events were similar among both treatment groups. Overall, the safety and efficacy of daptomycin were comparable with conventional therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Cosgrove, S. E., Sakoulas, G., Perencevich, E. N., Schwaber, M. J., Karchmer, A. W., & Carmeli, Y. (2003) · Clinical Infectious Diseases · doi:10.1086/345476 · Cited by 1,964
Engemann, J. J., Carmeli, Y., Cosgrove, S. E., Fowler, V. G., Bronstein, M. Z., Trivette, S. L., Briggs, J. P., Sexton, D. J., & Kaye, K. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367653 · Cited by 934
(2001) · American Journal of Infection Control · doi:10.1067/mic.2001.119952 · Cited by 559
Pfaller, M. A., Jones, R. N., Doern, G. V., Kugler, K., & Group, T. S. P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1762 · Cited by 539
Blot, S. I., Vandewoude, K. H., Hoste, E. A., & Colardyn, F. A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.19.2229 · Cited by 463
Graffunder, E. M. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf009 · Cited by 411
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Rybak, M. J., Hershberger, E., Moldovan, T., & Grucz, R. G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1062-1066.2000 · Cited by 362
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Self-citation
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Stevens, D. L., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, S. L., Montoya, J. G., & Wade, J. C. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu296 · Cited by 2,780
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
David, M. Z., & Daum, R. S. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00081-09 · Cited by 1,972
Lipsky, B. A., Berendt, A. R., Cornia, P. B., Pile, J. C., Peters, E. J. G., Armstrong, D. G., Deery, H. G., Embil, J. M., Joseph, W. S., Karchmer, A. W., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis346 · Cited by 1,766
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationAntibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Self-citationLodise, T. P., Patel, N., Lomaestro, B. M., Rodvold, K. A., & Drusano, G. L. (2009) · Clinical Infectious Diseases · doi:10.1086/600884 · Cited by 554
Straus, S. K., & Hancock, R. E. W. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.02.009 · Cited by 446
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
Gemmell, C. G., Edwards, D. I., Fraise, A. P., Gould, F. K., Ridgway, G. L., & Warren, R. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl017 · Cited by 439
Elyasi, S., Khalili, H., Dashti-Khavidaki, S., & Mohammadpour, A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1259-9 · Cited by 436
Review: Lessons Learned From Clinical Trials Using Antimicrobial Peptides (AMPs)
Dijksteel, G. S., Ulrich, M. M. W., Middelkoop, E., & Boekema, B. K. H. L. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.616979 · Cited by 428
The Nephrotoxicity of Vancomycin
Filippone, E., Kraft, W., & Farber, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.726 · Cited by 416
Natural products to drugs: daptomycin and related lipopeptide antibiotics
Baltz, R. H., Miao, V., & Wrigley, S. K. (2005) · Natural Product Reports · doi:10.1039/b416648p · Cited by 393
Complicated skin and soft tissue infection
Dryden, M. S. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq302 · Cited by 366
Benvenuto, M., Benziger, D. P., Yankelev, S., & Vigliani, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00247-06 · Cited by 319
Jauregui, L. E., Babazadeh, S., Seltzer, E., Goldberg, L., Krievins, D., Frederick, M., Krause, D., Satilovs, I., Endzinas, Z., Breaux, J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497271 · Cited by 312
Stryjewski, M. E., Graham, D. R., Wilson, S. E., O’Riordan, W., Young, D., Lentnek, A., Ross, D. P., Fowler, V. G., Hopkins, A., Friedland, H. D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/587896 · Cited by 289
Combinatorial biosynthesis of novel antibiotics related to daptomycin
Nguyen, K. T., Ritz, D., Gu, J.-Q., Alexander, D., Chu, M., Miao, V., Brian, P., & Baltz, R. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608589103 · Cited by 287
Bhavnani, S. M., Rubino, C. M., Ambrose, P. G., & Drusano, G. L. (2010) · Clinical Infectious Diseases · doi:10.1086/652767 · Cited by 280
Increasing Antibiotic Resistance among Methicillin‐Resistant Staphylococcus aureus Strains
Sakoulas, G., & Moellering, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/533592 · Cited by 274
Stryjewski, M. E., & Chambers, H. F. (2008) · Clinical Infectious Diseases · doi:10.1086/533593 · Cited by 268
Daptomycin: mechanisms of action and resistance, and biosynthetic engineering
Baltz, R. H. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.02.031 · Cited by 267
Mehta, S., Singh, C., Plata, K. B., Chanda, P. K., Paul, A., Riosa, S., Rosato, R. R., & Rosato, A. E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01525-12 · Cited by 142
Kowalski, T. J., Berbari, E. F., & Osmon, D. R. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.9.1201 · Cited by 132
Daptomycin in the Treatment of Patients with Infective Endocarditis: Experience from a Registry
Levine, D. P., & Lamp, K. C. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.07.011 · Cited by 105
Kullar, R., Casapao, A. M., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt294 · Cited by 99
Segreti, J. A., Crank, C. W., & Finney, M. S. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.347 · Cited by 88
Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00869-07 · Cited by 81
Metadata
- Authors
- Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-06-15
- Volume
- 38
- Issue
- 12
- Pages
- 1673-1681
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099481682
- Cited by
- 689
- References
- 25
- FWCI
- 31.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.